Press Release - May 13, 2008 - Earthtimes

Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008

Company Management to discuss the benefits of Hemodiafiltration therapy and Quality of Life for End-Stage Renal Disease Patients NEW YORK, May 13

NEW YORK, May 13 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider, today announced that it exhibited at the XLV ERA-EDTA Congress in Stockholm, Sweden.

Independent studies have demonstrated reductions of up to 35% in mortality risk using hemodiafiltration (HDF) therapy in place of other standard hemodialysis therapies. Additionally, reductions in drug requirements, lower morbidity and lower infection rates have been demonstrated in a range of studies substituting hemodiafiltration for hemodialysis.

The Nephros HDF system is designed to remove a range of harmful substances more effectively and more cost-effectively than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros's OLpur MD and H2H technologies are currently in pre-approval clinical trials in the U.S.

"Nephros's HDF technology represents a new standard of therapy for ESRD patients," said Norman J. Barta, Chairman and CEO of Nephros. "Our OLpur MD hemodiafilter series and our H2H module technologies are designed to provide a cost-effective and user-friendly means for hospitals and clinics to upgrade to mid-dilution HDF therapy without replacing their current dialysis machines." The Stockholm Congress will include technical presentations addressing various clinical performance advantages of Nephros mid-dilution HDF therapy.

About Nephros, Inc.

Nephros, Inc., headquartered in New York, is a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. Nephros products are sold and distributed throughout Europe and are currently being used in over fifty clinics in Europe.

Nephros also markets a line of water filtration products, the Dual Stage Ultrafilter (DSU) that produces biologically safe water. The Company's patented dual stage cold sterilization Ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses and parasites. The DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S.Marine Corps.

For more information on Nephros please visit the Company's website,
http://www.nephros.com.


Page Information

  • 5 months ago [history]
  • View page source
  • You're not logged in
  • No tags yet learn more

Wiki Information

Recent PBwiki Blog Posts